Beta2-adrenoreceptor ligands regulate osteoclast differentiation in vitro by direct and indirect mechanisms

Sarah J Aitken, Euphemie Landao-Bassonga, Stuart H Ralston, Aymen I Idris

Research output: Contribution to journalArticlepeer-review


Pharmacological modulators of beta-adrenoceptors can influence bone mineral density and fracture risk in humans. Studies reported that beta-adrenoceptor ligands stimulate bone resorption by enhancing the expression of RANK-L, whereas the mechanisms by which beta-adrenoreceptors regulate bone formation are poorly understood. Here we show that beta2-adrenoceptor is predominantly expressed by bone cells, although low levels of beta1- and beta3-adrenoceptors were detectable. Noradrenaline and the selective beta2-adrenoceptor agonists isoprenaline and salmeterol stimulated osteoclast formation and bone resorption in BM osteoblast co-cultures and increased expression of RANK-L by osteoblasts. All three ligands enhanced RANK-L induced osteoclast formation and increased osteoclast multinuclearity. There was no significant effect of noradrenaline or isoprenaline on osteoblast growth, differentiation or function. These findings confirm the importance of the sympathetic nervous system in the regulation of bone mass, and demonstrate that pharmacological agonists of beta2-adrenoceptors directly and indirectly stimulate osteoclast formation, but have no direct effect on osteoblast growth, differentiation or function.
Original languageEnglish
Pages (from-to)96-103
Number of pages8
JournalArchives of biochemistry and biophysics
Issue number1-2
Publication statusPublished - 2009


Dive into the research topics of 'Beta2-adrenoreceptor ligands regulate osteoclast differentiation in vitro by direct and indirect mechanisms'. Together they form a unique fingerprint.

Cite this